[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"blood-platelet-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:blood-platelet-disorder":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100639802","platelets-and-extracorporeal-membrane-oxygenation-veno-venous-100639802",false,"NCT07580469","Platelets and Extracorporeal Membrane Oxygenation Veno-venous","Study of PLATelet Functions and Risk Factors for Hemorrhagic Complications in Patients on Extracorporeal Membrane Oxygenation Veno-venous: Prospective Monocentric Cohort","PLAT-VV-ECMO","Inclusion Criteria:\n\n* Adults aged ≥ 18 years\n* No objection to participation in the study, obtained from a relative or trusted person; if no relative is available, inclusion under emergency procedure (pending patient or relative non-opposition)\n* Patients requiring admission to the general intensive care unit of Hôpital Rangueil for venovenous ECMO\n* Equipped with an arterial catheter for blood sampling\n* Ability to undergo the 4 blood draws relevant to the study\n* Receiving therapeutic anticoagulation with unfractionated heparin\n* Enrolled in a social security program or equivalent\n* No measures for Limitation and Withdrawal of Therapy have been implemented\n\nExclusion Criteria:\n\n* Minors\n* Patients under court-appointed guardianship or conservatorship\n* Pregnant or breastfeeding women\n* Hematological disease (leukemia, lymphoma) or constitutional thrombocytopenia\n* Platelet transfusion within 7 days prior to enrollment\n* Indication for immediate emergency ECMO preventing blood sampling before placement\n* Post-cardiotomy\n* Patient on antiplatelet therapy\n* Severe thrombocytopenia \\\u003C50 G\u002FL\n* Other invasive mechanical support such as Impella®, intra-aortic balloon pump, or Left Ventricular Assist Device (LVAD)","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","OBSERVATIONAL","In severe lung or heart disease, ExtraCorporeal Membrane Oxygenation (ECMO) may be used temporarily and can be responsible for major haemorrhagic complications. Thrombocytopenia and possibly thrombopathy promote bleeding. The primary objective is to characterize platelet dysfunction by aggregometry tests over time. Secondarily, investigators seek a correlation between haemorrhagic complications at day 10 and markers of platelet action and dysfunction; also, with the level of anticoagulation and inflammation by biomarkers.",[25,26,27,28],"Extracorporeal Membrane Oxygenation Complication","Hemorrhage","Blood Platelet Disorder","Thrombosis",[30,31,32,33,34],"VV-ECMO","Platelets","Thrombopathy","thrombo-haemorrhagic complications","thrombo-inflammation","NOT_YET_RECRUITING","2026-06-24",{"date":38,"type":39},"2026-06-29","ACTUAL",{"date":41,"type":21},"2026-09",{"date":43,"type":21},"2028-12-31",{"name":45,"class":46},"University Hospital, Toulouse","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":60,"studyType":22,"phases":4,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":47},"100557560","preoperative-hemogram-parameters-and-braf-molecular-test-detected-by-bethesda-3-cytology-100557560","NCT06539702","Preoperative Hemogram Parameters and BRAF Molecular Test Detected by Bethesda 3 Cytology.","To Reveal the Predictive Value of Preoperative Hemogram Parameters and BRAF Molecular Test in Predicting Malignancy in Cases With Thyroid Nodules Detected by Bethesda 3 Cytology.","Bethesda3","Inclusion Criteria:\n\n1. Patients between the ages of 18 -75\n2. Patients who were diagnosed with Bethesda III as a result of preoperative FNAC and decided to undergo thyroidectomy\n\nExclusion Criteria:\n\n1. Patients over 18 years old and under 75 years old\n2. Patients with malignancy detected in another focus with preoperative Bethesda III FNAC\n3. Detection of malignancy in another focus other than the nodule with Bethesda III cytological result after thyroidectomy\n4. Failure to obtain preoperative hemogram results Patients who do not agree to participate in scientific studies for BRAF testing",true,"75 Years",{"count":59,"type":21},120,"7 Days","The main hypothesis of this study is that preoperative hemogram parameters can be used as biomarkers for malignancy in patients with thyroid nodule Bethesda 3 cytology.\n\nThe secondary hypothesis is that BRAF molecular testing has a high predictive value in predicting malignancy in patients with thyroid nodule Bethesda 3 cytology.\n\nPrimary outcome: Preoperative hemogram parameters. Secondary outcome: BRAF positivity.",[27,63,64,65],"BRAF V600E","Thyroid Nodule","Cytologic Atypia",[67,68,69,70],"Thyroid","carcinoma","Bethesda 3","BRAF","RECRUITING","2024-08-01",{"date":74,"type":39},"2024-08-06",{"date":76,"type":39},"2024-07-20",{"date":78,"type":21},"2024-08-15",{"name":80,"class":46},"Saglik Bilimleri Universitesi"]